Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis

Aliment Pharmacol Ther. 2017 Jan;45(2):376-378. doi: 10.1111/apt.13861.

Authors

K Hartery^{1

2}, S O'Reilly^{1

2}, D Houlihan^{2

3}, G Doherty^{1

2}, H Mulcahy^{1

2}, G Cullen^{1

2}, J Sheridan^{1

2}

Affiliations

¹ Department of Gastroenterology, Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.
² School of Medicine, University College Dublin, Dublin, Ireland.
³ National Liver Unit, St. Vincent's University Hospital, Dublin, Ireland.

PMID: 27933688
DOI: 10.1111/apt.13861

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Cholangitis, Sclerosing*
Humans
Inflammatory Bowel Diseases
Liver Transplantation*

Substances

Antibodies, Monoclonal, Humanized
vedolizumab